Business Context and Reporting Period
Company: Akers Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 13, 2017
Event: Exercise of over-allotment option in a public offering.
Key Financial Metrics
This filing reports a specific capital raising event rather than periodic financial performance. The filing text does not provide values for revenue, profit, cash flow, margins, or existing debt levels.
- Additional Shares Issued: 122,500 shares of common stock.
- Price Per Share: $1.20 (before underwriting discounts and commissions).
- Additional Warrants Issued: Warrants to purchase up to 61,250 shares.
- Warrant Exercise Price: $1.50.
- Underwriter: Joseph Gunnar & Co., LLC.
Material Changes
The material change reported is the increase in the Company's outstanding share count and warrant obligations due to the underwriter's election to exercise the over-allotment option. This action follows the initial public offering announced on January 10, 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of the equity issuance. The primary contingency noted is the completion of the share and warrant issuance as described in the press release.
Investor Verification Checklist
- Verify the total gross proceeds generated from the initial offering plus the over-allotment exercise.
- Confirm the updated total number of authorized and outstanding shares of common stock post-issuance.
- Review the underwriting agreement to determine the specific discount and commission rates deducted from the $1.20 per share price.
- Check the terms of the newly issued warrants, including expiration dates and exercise conditions.